Orvepitant (GW823296) is a compound with the ability to inhibit pruritus induced by cancer epidermal growth factor receptor inhibitor (EGFRI) and is a neurokinin-1 receptor antagonist.
References
[1] Neurokinin-1 antagonist orvepitant for EGFRI-induced pruritus in patients with cancer: a randomised, placebo-controlled phase II trial DOI:10.1136/bmjopen-2019-030114